Developing and shedding inhibitions: How MHC class II molecules reach maturity

Current Opinion in Immunology

Volumn 8, Issue 1, 1996, Pages 51-58

  Busch, Robert ^a   Mellins, Elizabeth D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HLA D ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ENDOSOME; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW;

EID: 0029864967     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80105-1     Document Type: Article

References (77)

1. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76:287-299.
2. Stem LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368:215-221.
3. Rammensee H-G, Friede T, Stephanovic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228. This is a comprehensive overview of structural preferences for peptide binding to MHC class I and class II molecules, obtained from X-ray crystallography, characterization of MHC-bound peptides, and sequence alignment.
4. Marks MS, Germain RN, Bonifacino JS: Transient aggregation of major histocompatibility complex class II chains during assembly in normal spleen cells. J Biol Chem 1995, 270:10475-10481. This paper shows that nascent α and β chains form high molecular weight aggregates as a normal class II assembly intermediate. Ii appears to rescue these chains from the aggregates rather than prevent aggregate formation.
5. Anderson KS, Cresswell P: A role for calnexin (IP90) in the assembly of class II molecules. EMBO J 1994, 13:675-682.
6. Cresswell P: Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994, 12:259-293.
7. Roche PA, Teletski CL, Stang E, Bakke O, Long EO: Cell surface HLA-DR invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993, 90:8581-8585.
8. Bénaroch P, Yilla M, Raposo G, Ito K, Miwa K, Geuze HJ, Ploegh HL: How MHC class II molecules reach the endocytic pathway. EMBO J 1995, 14:37-49.
9. Wolf PR, Ploegh HL: How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Biol 1995, 11:267-306.
10. Pieters J, Bakke O, Dobberstein B: The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993, 106:831-842.
11. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis CD, Collawn JF: Sorting signals in the MHC class II Invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment J Cell Biol 1994, 126:317-330.
12. Motta A, Bremmes B, Castiglione Morelli MA, Frank RW, Saviano G, Bakke O: Structure-activity relationship of the leucine-based sorting motifs in the cytosolic tail of the major-histocompatibility complex-associated invariant chain. J Biol Chem 1995, 270:27165-27171. This study provides evidence that the targetting motifs in the cytoplasmic tail of li are in α-helical structures, creating a 'signaling patch' along one face of the helix.
13. Pinet V, Vergelli M, Martin R, Bakke O, Long EO: Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995, 375:603-606. Parallel effects of class II cytoplasmic tail mutations on class II recycling and presentation of some antigens implicate li-independent recycling in the presentation of a subset of exogenous antigens.
14. Calafat J, Nijenhuis M, Janssen H, Tulp A, Dusseljee S, Wubbolts R, Neefjes JJ: Major histocompatibility complex class II molecules induce the formation of endocytic MIIC-like structures. J Cell Biol 1994, 126:967-977
15. Amigorena S, Webster P, Drake J, Newcomb J, Cressweli P, Mellman I: Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles. J Exp Med 1995, 181:1729-1741. This paper shows that in a mouse B lymphoma, both end-stage li processing and peptide loading occur in class II vesicles (CIIV), a low density class II-containing endocytic compartment previously discovered by the same group.
16. Maric MA, Taylor MD, Blum JS: Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 1994, 91:2171-2175.
17. Xu M, Capraro GA, Daibata M, Reyes VE, Humphreys RE: Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol 1994, 31:723-731.
18. Avva RR, Cresswell P: In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994, 1:763-774. Using an anti-CLIP antibody, CLIP is shown to be an intermediate in li removal from class II molecules in vitro and in vivo. Specific detergents, such as octylglucoside, are shown to stimulate CLIP release from class II.
19. Kelly AP, Monaco JJ, Cho S, Trowsdale J: A new human HLA class 11-related locus, DM. Nature 1991, 353:571-573.
20. Cho S, Attaya M, Monaco JJ: New class II-like genes in the murine MHC. Nature 1991, 353:573-576.
21. Karlsson L, Péléraux A, Lindstedt R, Liljedahl M, Peterson PA: Reconstitution of an operational MHC class II compartment In nonantigen-presenting cells. Science 1994, 266:1569-1573. This study shows that both DM/H2-M and li are needed for optimum peptide loading of class II molecules in HeLa transfectants. It also shows that li binds to H2-M but is not required for endosomal transport.
22. Denzin LK, Cresswell P: HLA-DM induces CLIP dissociation from MHC class Ii αβ dimers and facilitates peptide loading. Cell 1995, 82:155-165. This paper shows that affinity-purified DM in detergent catalyzes formation of SDS stable complexes from DR3-CLIP complexes and antigenic peptides, in part by catalyzing CLIP removal.
23. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D: Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990, 343:71-74.
24. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R et al.: Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant Science 1992, 258:1801-1804.
25. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P: HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992, 360:474-477
26. Riberdy JM, Avva RR, Geuze HJ, Cresswell P: Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines. J Cell Biol 1993, 125:1225-1237.
27. Mellins E, Cameron P, Amaya M, Goodman S, Pious D, Smith L, Arp B: A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med 1994, 179:541-549.
28. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E: An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994, 368:551-554.
29. Fling SP, Arp B, Pious D: HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994, 368:554-558.
30. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P: Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 Cells. Immunity 1994, 1:1-20. This paper and [28,29] show that transfection of DMA/DMB genes into antigen presentation mutant cells restores CLIP exchange for antigenic peptides. Immunoprecipitation shows DM to be an αβ heterodimer that is transported into post-Golgi compartments without involvement of li and is long-lived, but is not detected at the cell surface.
31. Xu X, Song W, Cho H, Qiu Y, Pierce SK: Intracellular transport of Invariant chain-MHC class II complexes to the peptide-loading compartment J Immunol 1995, 155:2984-2992. The authors extend their previous work on two endosomal class II compartments in mouse B cells, one containing class II-li, the other containing class II-peptide. Slowing Ii breakdown with leupeptin shows that li removal occurs in the latter compartment; the former is most likely a transport vesicle.
32. Tulp A, Verwoerd D, Dobberstein B, Ploegh HL, Pieters J: Isolation and characterization of the intracellular MHC class II compartment. Nature 1994, 369:120-126.
33. West MA, Lucocq JM, Watts C: Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 1994, 369:147-150.
34. Sanderson F, Klejmeer MJ, Kelly A, Verwoerd D, Tulp A, Neefjes JJ, Geuze HJ, Trowsdale J: Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 1994, 266:1566-1569. Anti-DM antisera are employed to demonstrate that DM is an αβ heterodimer that accumulates intracellularly in MIIC of melanoma cells.
35. Mellman I, Pierre P, Amigorena S: Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. Curr Opin Cell Biol 1995, 7:564-572.
36. Green JM, DeMars R, Xu X, Pierce SK: The intracellular transport of MHC class II molecules in the absence of HLA-DM. J Immunol 1995, 154:3759-3768 This study shows that HLA-DM is present in high density class II peptide loading compartments of human Epstein-Barr virus (EBV)-transformed B cells, but it is not required for targeting of class II molecules to these compartments.
37. Castellino F, Germain RN: Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway and appearance of peptide-loaded class II in multiple compartments. Immunity 1995, 2:73-88. This paper shows that intracellular class II-li and class II-peptide complexes are present in several distinct subcellular fractions on gradients prior to cell surface appearance.
38. Lanzavecchia A: How can cryptic epitopes trigger autoimmunity? J Exp Med 1995, 181:1945-1948.
39. Bijlmakers M-JJE, Benaroch P, Ploegh HL: Assembly of HLA-DR1 molecules translated in vitro: binding of peptide in the endoplasmlc reticulum precludes association with invariant chain. EMBO J 1994, 13:2699-2707.
40. Long EO, LaVaute T, Pinet V, Jaraquemada D: Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide. J Immunol 1994, 153:1487-1494.
41. Busch R, Vturina IY, Drexler J, Momburg F, Hämmerling GJ: Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur J Immunol 1995, 25:48-53.
42. Bikoff EK, Germain RN, Robertson EJ: Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity 1995, 2:301-310.
43. Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN: MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 1994, 370:647-650.
44. Busch R, Cloutier I, Sékaly RP, Hämmerling GJ: Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996, in press. This study shows allele-specific polypeptide binding to unprotected class II molecules in the ER. Endosomal peptide loading is also seen in cells capable of li-independent endosomal targeting of class II molecules.
45. Bodmer H, Viville S, Benoist C, Mathis D: Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 1994, 263:1284-1286.
46. Freisewinkel IM, Schenck K, Koch N: The segment of Invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 1993, 90:9703-9706.
47. Bijlmakers M-JE, Benaroch P, Ploegh HL: Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med 1994, 180:623-629.
48. Romagnoli P, Germain RN: The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport and peptide occupancy. J Exp Med 1994, 180:1107-1113.
49. •] show that the li 118-193 fragment is a trimeric, α-helical coiled coil, whereas the CLIP region of li is disordered. A second segment of li that is carboxy-terminal to CLIP and binds outside the groove is identified.
50. •].
51. Morkowski S, Goldrath AW, Eastman S, Ramachandra L, Freed DC, Whiteley P, Rudensky AY: T cell recognition of MHC class II complexes with invariant chain processing intermediates. J Exp Med 1995, 182:1403-1413. This study shows that human CLIP can be recognized by a monoclonal antibody and by mouse T cells in a class II-restricted fashion, strongly suggesting a similarity between CLIP and antigenic peptides. The antibody also reacts with αβ-p22li complexes.
52. •] (which extends the work to four DR alleles) show that anchor residues of CLIP use similar specificity pockets for class II binding as antigenic peptides do.
53. •].
54. Sette A, Southwood S, Miller J, Appella E: Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 1995, 181:677-683. Using gel filtration binding assays, this paper and [55] define hierarchies of MHC class II alleles with differing propensities for stable CLIP binding.
55. Liang MN, Beeson C, Mason K, McConnell HM: Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC, Int Immunol 1995, 7:1397-1404.
56. Gautam AM, Pearson C, Quinn V, McDevitt HO, Milburn PJ: Binding of an invariant chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1995, 92:335-339.
57. Ghosh P, Amaya M, Mellins E, Wiley DC: The structure of HLA-DR3 complexed with CLIP, an intermediate in peptide loading. Nature 1995, 387:457-462. The X-ray structure of a CLIP-DR3 complex shows the core region of CLIP (li 90-101) to bind in the antigen binding groove very much like antigenic peptides.
58. Mehringer JH, Harris MR, Kindle CS, McCourt DW, Cullen SE: Characterization of fragments of the murine la-associated invariant chain. J Immunol 1991, 146:920-927.
59. Newcomb JR, Cresswell P: Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo. J Immunol 1993, 151:4153-4163.
60. Ericson ML, Sundstrøm M, Sansom DM, Charron DJ: Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. J Biol Chem 1994, 269:26531-26538.
61. Karp DR, Jenkins RN, Long EO: Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins. Proc Natl Acad Sci USA 1992, 89:9657-9661.
62. Kropshofer H, Vogt A-B, Hämmerling GJ: Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci USA 1995, 92:8313-8317.
63. Kropshofer H, Vogt A-B, Stern LJ, Hämmerling GJ: Self-release of CLIP in peptide loading of HLA-DR molecules. Science 1995, 270:1357-1359. This paper and [62,65] explore the role of amino-terminal CLIP regions in destabilizing peptide-class II complexes. The results suggest that, as part of intact CLIP, li81-89 promotes CLIP release and, as an isolated peptide, it can enhance dissociation of unrelated peptides as well as core CLIP.
64. Vogt A-B, Kropshofer H, Stern LJ, Amshoff C, Dobberstein B, Hämmerling GJ: Interference of distinct Invariant chain regions with, superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol 1995, 155:4757-4765. This study maps regions of li that flank core CLIP and interact with the SEB binding site of class II molecules. Antigenic peptides shift class II to a conformation that no longer binds these peptides.
65. Adams S, Humphreys RE: Invariant chain peptides enhancing or Inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 1995, 25:1693-1702.
66. Urban RG, Chicz RM, Strominger JL: Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med 1994, 180:751-755.
67. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM: Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995, 375:802-806. This study shows that sDM enhances loading of class II molecules with antigenic peptides by catalyzing the release of pre-bound peptides including CLIP.
68. Monji T, McCormack AL, Yates JR III, Pious D: Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. J Immunol 1994, 153:4468-4477.
69. Sherman MA, Weber DA, Jensen PE: DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995, 3:197-205. Shows that peptide binding to DR in reconstituted membranes is enhanced by membrane preparations from DM positive but not DM negative cells. The effect is attributed to an enhancement of CLIP dissociation by DM.
70. Nelson CA, Petzold SJ, Unanue ER: Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature 1994, 371:250-252.
71. •].
72. k expressed in DM mutants is almost fully functional in antigen presentation. T2 cells are shown to express decreased levels of some endosomal proteases, possibly accounting for the low rate of li proteolysis and distended endosomes reported for T2 cells [25].
73. d class II molecules. SDS stability was to some extent DM dependent but a set of T-cell determinants was presented well in the absence of DM.
74. •] show a critical role for a Tyr-Thr-Pro-Leu sequence in the DMβ chain cytoplasmic tail in endosomal targeting of HLA-DM via cell-surface recycling and direct TGN pathways.
75. •].
76. Müller K-P, Schumacher J, Kyewski BA: Half-life of antigen/major histocompatibility complex class II complexes in vivo: Intra-and interorgan variations. Eur J Immunol 1993, 23:3203-3207.
77. k. Proc Natl Acad Sci USA 1994, 91:12463-12466.